Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 192

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 192
---
1,870,123

    Accumulated other comprehensive (loss) income

    8

    (204
    )

    Accumulated deficit

    (2,054,553
    )

    (1,969,150
    )

    Total stockholders’ equity (deficit)

    (97,283
    )

    (99,231
    )

    Total liabilities and stockholders’ equity (deficit)
     
    $
    109,098

    $
    165,504

 See accompanying notes to the consolidated financial statements.

99

Atara Biotherapeutics, Inc. 

Consolidated Statements of Operations and Comprehensive Loss 

(In thousands, except per share amounts)

    Years Ended December 31,

    2024

    2023

    Commercialization revenue
     
    $
    128,940

    $
    7,886

    License and collaboration revenue

    —

    687

    Total revenue

    128,940

    8,573

    Costs and operating expenses:

    Cost of commercialization revenue

    21,009

    8,886

    Research and development expenses

    151,483

    224,785

    General and administrative expenses

    39,886

    50,908

    Total costs and operating expenses

    212,378

    284,579

    Loss from operations

    (83,438
    )

    (276,006
    )

    Other income (expense), net:

    Interest income

    2,110

    5,426

    Interest expense

    (4,615
    )

    (5,285
    )

    Other income (expense), net:

    528

    (246
    )

    Total other income (expense), net

    (1,977
    )

    (105
    )

    Loss before provision for (benefit from) income taxes

    (85,415
    )

    (276,111
    )

    Provision for (benefit from) income taxes

    (12
    )

    15

    Net loss
     
    $
    (85,403
    )
     
    $
    (276,126
    )

    Other comprehensive gain (loss):

    Unrealized gain (loss) on available-for-sale securities

    212

    1,863

    Comprehensive loss